Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 9Cetuximab 9Radiotherapy, Intensity-Modulated 7Everolimus 4Docetaxel 3Carboplatin 3Biopsy 3130-nm albumin-bound paclitaxel 3Ultrasonography 2Taxes 2Radiotherapy 2Radiation 2Photochemotherapy 2Paclitaxel 2Microarray Analysis 2Immunohistochemistry 2Gene Expression Profiling 2Fluorouracil 2Erlotinib Hydrochloride 2Cryosurgery 2Albumin-Bound Paclitaxel 21-phenyl-3,3-dimethyltriazene 2temoporfin 1talactoferrin alfa 1sargramostim 1pimonidazole 1pembrolizumab 1Zinc Oxide 1X-Rays 1Vaccinium myrtillus extract 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Tongue Neoplasms × VTX-2337 × Clear all
NCT01334177 2015-03-05

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

University of Washington

Phase 1 Completed
13 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡